CU Startup News
This innovative battery technology company raised $542.9 million by going public through a reverse merger with stocks now appearing on the Nasdaq exchange.
ColdQuanta CEO Scott Faris was featured on the "Innovating with Scott Amyx" podcast to talk about the future of the ¾«Æ·SMÔÚÏßӰƬ-founded business and commercialization within academia.
Chemical & Engineering News (C&EN) identified young scientists who are trying to solve formidable global problems. Lim was recognized for developing organic molecules that spur on light-powered reactions.
¾«Æ·SMÔÚÏßӰƬ startup ColdQuanta, JILA physicists, and other university innovators are featured in a new film from the Colorado Office of Economic Development and International Trade (OEDIT) promoting Colorado's extensive quantum ecosystem.
Respirogen, a company whose research is led by Biomedical Engineering Program Director Mark Borden and founded by Borden’s former student, Paul Mountford (PhDMechEngr’15), has developed microbubbles that can deliver oxygen to the blood stream independent of the lungs.
Co-founded by ¾«Æ·SMÔÚÏßӰƬ professor Mike McGehee, Tynt has raised $8.5 million in seed funding to scale its reversible metal electrodeposition (RME) technology, which is used to create blackout windows that aim to increase home comfort, privacy and energy efficiency.
Otoro Energy, spun out of technology developed in Assistant Professor Michael Marshak's lab at ¾«Æ·SMÔÚÏßӰƬ, has received $4.14M from the U.S. Department of Energy to improve the cost, scalability and performance of existing flow battery technology through a metal chelate flow battery system.
The Louisville-based ¾«Æ·SMÔÚÏßӰƬ startup company is moving into a 75,000-square-foot building in Thornton. The expansion comes as the company prepares to go public. In June, Solid Power announced a merger valued at $1.2B with Decarbonization Plus Acquisition Corp. III.
Meati Foods is a CU spinout company hoping that fungi, not plants, could be key to winning the protein wars and confronting climate change. Co-founders Tyler Huggins and Justin Whiteley met as Ph.D. students at ¾«Æ·SMÔÚÏßӰƬ, where Whiteley studied material science and Huggins studied environmental engineering.
Xalud Therapeutics is a clinical-stage biotechnology company developing therapies initially worked on and developed at ¾«Æ·SMÔÚÏßӰƬ for the treatment of neuro-inflammatory diseases and inflammatory joint disorders, including osteoarthritis and rheumatoid arthritis.